Drug-induced weight loss may potentially extend the lifespan of Americans, according to project findings by researchers.
In a groundbreaking development, researchers at Swiss Re project a significant reduction in all-cause mortality in the U.S. by 2045, attributed largely to GLP-1 drugs. These medications, primarily used for type 2 diabetes and weight loss, could potentially save millions from premature death by improving baseline risk factors.
The benefits of GLP-1 drugs extend beyond weight loss and diabetes management. According to Dr. Sue Decotiis, a triple board-certified weight loss physician based in New York, these drugs can improve a variety of conditions, including heart, kidney, liver, and skin conditions, arthritis, cognitive decline, addiction, and certain cancers.
Dr. Decotiis explains that GLP-1 medications work by reducing the volume of fat cells in the body, which in turn reduces inflammatory cytokines. However, it's crucial to note that without sustainable changes, weight regain and rebound effects are common.
The development of GLP-1 drugs for weight reduction and diabetes therapy was initiated by the pharmaceutical company Novo Nordisk, based in Denmark. The company introduced semaglutide-based treatments like Wegovy starting from 2023, and is recognized as a key pioneer in this field with patents lasting until 2031-2032 in various regions.
Paul Murray, the CEO of Swiss Re's Life & Health Reinsurance, believes GLP-1 drugs hold 'significant promise to help us beat the obesity epidemic.' As insurers, Swiss Re is in a position to build partnerships, support policy, and encourage people to make meaningful lifestyle changes with a focus on prevention.
Murray emphasises that the full benefit of GLP-1 drugs will come from implementing lifestyle changes beyond medication. It's important to treat GLP-1 drugs with respect, treat your body with respect, and understand that they are a wonderful tool if used the right way, according to Dr. Decotiis. To maximise the benefits of GLP-1 medications, individuals should implement lifestyle changes for long-term health improvements, including diet and exercise.
In the U.K., more than a 5% reduction in mortality is projected over the same 20 years due to GLP-1 drugs. America, which has the world's highest obesity rate, with over 40% of the adult population being obese, stands to benefit greatly from these drugs.
Angelica Stabile, a lifestyle reporter for our website Digital, will continue to follow this developing story and bring you updates on the impact of GLP-1 drugs on public health.
*Note: This article is for informational purposes only and not intended as medical advice. Always consult with a healthcare professional before starting any new treatment.
